Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Leukemia, Myeloid, Acute 1Glioblastoma 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × glasdegib × Clear all
NCT03466450 2024-03-28

GEINOGLAS

Grupo Español de Investigación en Neurooncología

Phase 1/2 Completed
75 enrolled
CNS

Glioblastoma

NCT03390296 2023-09-05

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Completed
50 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡